GlassScriptPhysician profile
Abbass Hamze
NPI 1952945529
$657.35
in general payments reported to CMS, 2019-2025
13 companies · $322 in 2025
The $322 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $183 · 2023: $42.78 · 2024: $110 · 2025: $322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $474.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $474.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $218.61 | 2022-2025 | Zepbound |
| Alnylam Pharmaceuticals INC. | $63.97 | 2024 | Amvuttra |
| Novo Nordisk INC | $62.41 | 2025 | Ozempic, Wegovy |
| Exact Sciences Corporation | $61.59 | 2023-2025 | Cologuard Collection Kit |
| Boston Scientific Corporation | $48.84 | 2024-2025 | Wavewriter Alpha Prime 16 |
| Pfizer INC. | $34.09 | 2025 | |
| Cipher Pharmaceuticals US LLC | $33.00 | 2025 | Spinosad, Natroba |
| Dexcom, INC. | $30.44 | 2022 | |
| Abbvie INC. | $25.20 | 2022 | |
| Glaxosmithkline, LLC. | $22.74 | 2025 | Trelegy Ellipta |
| Abbott Laboratories | $22.34 | 2023 | Diamondback Peripheral |
| Insmed, INC. | $18.62 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $15.50 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abbass Hamze listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.